NL-OMON35311已完成不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC AND FOOD EFFECT OF BCI 838 AND AN OPEN-LABEL MINIDOSE BIOAVAILABILITY STUDY TO COMPARE SEVERAL BCI-632 PRO-DRUG CANDIDATES IN HEALTHY MALE SUBJECTS - BCI-838 SAD and minidose bioavailability study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy male
- •- 18-55 years of age, inclusive
- •- BMI 18-30 kg/m2, inclusive
- •- non-smoker or moderate smoker (* 5 cigarettes per day)
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of the study.
研究者
相似试验
招募中
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE ASCENDING DOSE TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LEO 158968 IN HEALTHY SUBJECTSNL-OMON53439eo Pharma120
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND THE EFFECT OF FOOD AND KETOCONAZOLE ON THE PHARMACOKINETICS OF IPI-145 WHEN ADMINISTERED TO HEALTHY ADULT SUBJECTSblood malignanciesinflammatory diseases1002432410027665NL-OMON35436Infinity Pharmaceuticals106
已完成
4 期
A clinical study to assess the benefits of Concentrace Trace Mineral Drops-(CTMD®), a food supplement in subjects with OSTEOARTHRITIS (OA) of knee jointCTRI/2010/091/001105Dr. Himanshu Bansal100
已完成
2 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUStype 2 diabetes mellitus10012653diabetesNL-OMON34301Hanmi Pharmaceutical Company Ltd48
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS - HM11260C SAD study in patients with type 2 diabetes mellitustype 2 diabetes mellitusMedDRA version: 12.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2010-019665-28-NLHanmi Pharmaceutical Company Limited